• About Hair Loss
  • Stemson Solution
    • Stemson Solution
    • Hair Follicle Biology
  • Company
    • Stemson Background
    • Team
    • Contact
  • Careers
  • News
Logo
  • About Hair Loss
  • Stemson Solution
    • Stemson Solution
    • Hair Follicle Biology
Logo
  • Company
    • Stemson Background
    • Team
    • Contact
  • Careers
  • News

News

Stemson’s Cornerstone Patent Approved in US

September 14, 2020

Stemson Therapeutics announced approval in the United States of US patent No. 10716808, entitled “Methods and compositions to modulate hair growth” licensed exclusively from the Sanford Burnham Prebys Medical Discovery Institute.  The patent covers a novel process developed by Stemson co-founder and Chief Scientific Officer, Alexey Terskikh, PhD, to differentiate Induced Pluripotent Stem Cells (iPSC) into dermal papilla cells, the cell type primarily responsible for controlling hair follicle generation and hair cycling.  Issuance of this foundational patent provides stability surrounding the company’s efforts to develop its breakthrough iPSC-based solution for hair growth.

Read More »

Stemson Appoints Meghan Samberg, PhD, as Vice President, R&D and Preclinical Development

September 8, 2020

Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development.  Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.

“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team.  Her expertise in tissue engineering strategies,

Read More »

Stemson Appoints Cenk Sumen, PhD, as Chief Technology Officer and Member of Board of Directors

September 11, 2019

Stemson Therapeutics is pleased to announce Cenk Sumen, PhD, will join our team as Chief Technology Officer.  Dr. Sumen will lead Stemson’s manufacturing efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.  He will join Stemson’s executive team, reporting to Geoff Hamilton, Chief Executive Officer of Stemson, and will serve on the company Board of Directors.

“Cenk brings almost a decade of experience translating early stage cell therapy candidates into GMP compliant manufacturing environments.  

Read More »

Stemson Secures Multi-Million Dollar Investment from Allergan

June 27, 2019

Today, Stemson Therapeutics announced a significant investment in its seed financing round by Allergan, a leading global pharmaceutical company. The investment will advance Stemson’s final product development in preparation for human clinical trials, and provide Allergan with a promising new product pipeline for its market leading Medical Aesthetics portfolio.  The investment with Stemson represents Allergan’s first step into iPSC-based cell therapy technology.  iPSC’s have the potential to become any cell type in the human body and hold great promise to deliver breakthrough regenerative medicine therapies in the future. 

Read More »

Demonstration of Functional Hair Follicle Growth From Stem Cells

June 26, 2019

Sanford Burnham Prebys scientist and Stemson Therapeutics Co-Founder demonstrates functional hair follicles grown from stem cells at International Society for Stem Cell Research (ISSCR) annual meeting.

Download the press release

Read More »

Researchers From The Sanford Burnham Prebys Medical Discovery Institute Win Awards For Hair Follicle Regeneration Solution

May 31, 2019

Sanford Burnham Prebys Medical Discovery Institute researchers Dr. Alexey Terskikh and Dr. Antonella Pinto have won a prize for best poster at the 2019 UC San Diego Division of Regenerative Medicine Symposium and a merit award for best abstract at the 2019 International Society for Stem Cell Research Annual Meeting.  The poster and abstract highlighted the use of Dermal Papilla cells derived from human Induced Pluripotent Stem Cells (iPSC) to grow partially humanize de novo hair follicles in nude mice. 

Read More »

Stemson Therapeutics Welcomes Dr. David H Sachs As A Key Consultant On Hair Growth Solution

May 24, 2019

David H Sachs, MD, a renowned transplant immunologist at Columbia University Medical Center and Massachusetts General Hospital, will serve as a key consultant in guiding the testing and development of Stemson Therapeutics’ hair growth cell therapy.  Dr. Sachs brings over 45 years of experience in testing transplantation tolerance of allografts and xenografts.  He is the author of over 700 articles in scientific journals and has pioneered the development of animal models to test transplantation tolerance.

Read More »

Stemson Therapeutics Establishes Headquarters on the Sanford Burnham Prebys Medical Discovery Institute Campus in La Jolla, CA

April 15, 2019

Stemson Therapeutics has established its headquarters in La Jolla, CA on the Sanford Burnham Prebys Medical Discovery Institute (SBP) campus, centered in one of the premier biomedical research hubs in the United States.  Stemson’s unique cell therapy solution to treat alopecia is based on Induced Pluripotent Stem Cell (iPSC) technology originally developed at SBP by Stemson co-founder, Dr. Alexey Terskikh.  By incubating within the institute, Stemson will have access to world class research and development facilities to support the final product development in preparation for clinical trials.

Read More »

Stemson Therapeutics Appoints Matt Posard as Executive Chairman of the Board

March 14, 2019

Matt Posard, former senior executive at Illumina, has joined the Stemson Therapeutics team as Executive Chairman of the Board.  Matt brings over 30 years of executive experience in the life sciences industry.  He helped grow three companies – BioSite, GenProbe and Illumina – from early stage commercialization to major global success.  He is a seasoned board member and currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Dermtech, Talis BioMedical, Ingite Bio, and Fabric Genomics.

Read More »

Stemson Therapeutics Forms Scientific and Medical Advisory Board

January 1, 2019

Stemson Therapeutics welcomes Dr. Hideyuki Okano and Dr. Michael Rendl as scientific advisors, as well as Dr. Richard Chaffoo and Dr. Paul McAndrews as medical advisors. Okano is a stem cell biologist with deep experience in Induced Pluripotent Stem Cells (iPSC) and their translation into therapeutic use.  Dr. Rendl is a stem cell biologist focusing on hair follicle formation.  Together, Drs. Okano and Rendl will guide the scientific and biological development of the Stemson Therapeutics hair growth cell therapy.

Read More »
« Previous 1 2
Logo

© 2023 Stemson Therapeutics Corporation. All rights reserved.

  • LEARN MORE
    • About Hair Loss
    • Stemson Solution
    • Hair Follicle Biology
  • ABOUT US
    • Stemson Background
    • Team
    • News
    • Careers
  • SUPPORT
    • Contact
    • Privacy Policy